1-9 of 9
Bahija Jallal
Close
Sort by
Journal Articles

Population Pharmacokinetics of Siplizumab (MEDI-507), a Humanized Anti-CD2 Monoclonal Antibody, in Cancer Patients.

Chunlin Chen, MD, PhD, John E Janik, MD, Karen Kaucic, MD, Lorin Roskos, PhD, Bahija Jallal, PhD, Gabriel J. Robbie, PhD
Journal: Blood
Blood (2009) 114 (22): 2670.
https://doi.org/10.1182/blood.V114.22.2670.2670
Published: 2009
Journal Articles

The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells

Mohammad Luqman, Sha Klabunde, Karen Lin, Georgios V. Georgakis, Anu Cherukuri, Jocelyn Holash, Cheryl Goldbeck, Xiaomei Xu, Edward E. Kadel, III, Sang Hoon Lee, Sharon Lea Aukerman, Bahija Jallal, Natasha Aziz, Wen-Kai Weng, William Wierda, Susan O'Brien, Anas Younes
Journal: Blood
Blood (2008) 112 (3): 711–720.
https://doi.org/10.1182/blood-2007-04-084756
Published: 2008
Journal Articles

A Non-Internalizing Anti-CD40 Antibody, CHIR-12.12, Blocks CD40L-Induced Cytokine Production and Mediates Greater ADCC Than Rituximab in Primary CLL Cells.

Xia Tong, MSc, Sharon Lea Aukerman, PhD, Karen Lin, BS, Natasha Aziz, PhD, Cheryl Goldbeck, BS, Georgios V. Georgakis, MD, Anas Younes, MD, Wen-Kai Weng, MD, PhD, Susan O’Brien, MD, William Wierda, MD, PhD, Bahija Jallal, PhD, Mohammad Luqman, PhD
Journal: Blood
Blood (2005) 106 (11): 2964.
https://doi.org/10.1182/blood.V106.11.2964.2964
Published: 2005
Journal Articles

Human Antagonistic Anti-CD40 Antibody, CHIR-12.12, Inhibits CD40-Mediated Survival of Chronic Lymphocytic Leukemia B Cells Leading to Cellular Apoptosis.

Anu Cherukuri, PhD, Edward Kadel, BS, Sang H. Lee, PhD, Cheryl Goldbeck, BS, Carla Heise, PhD, Mohammad Luqman, PhD, Sharon L. Aukerman, PhD, Natasha Aziz, PhD, Susan O’Brien, MD, William G. Wierda, MD, PhD, Bahija Jallal, PhD
Journal: Blood
Blood (2005) 106 (11): 2965.
https://doi.org/10.1182/blood.V106.11.2965.2965
Published: 2005
Journal Articles

CHIR-258 Efficacy in a Newly Developed Preclinical Bone Marrow Model of t(4;14) Multiple Myeloma.

Xiaohua Xin, PhD, Yan Tang, MD, Yoko Oei, BA, Helen Ye, BS, Daniel Menezes, PhD, Katherine Rendahl, PhD, Paul Hollenbach, MS, Nancy Pryer, PhD, Suzanne Trudel, MD, Dirk Mendel, PhD, Bahija Jallal, PhD, Carla Heise, PhD
Journal: Blood
Blood (2005) 106 (11): 3449.
https://doi.org/10.1182/blood.V106.11.3449.3449
Published: 2005
Journal Articles

Antagonist Anti-CD40 Antibody, CHIR-12.12, Induces ADCC, Inhibits Tumor Growth, and Prolongs Survival in a Human Multiple Myeloma Xenograft Model.

Li Long, PhD, Xia Tong, M.Sc, Montesa Patawaran, B.Sc, Sharon L. Aukerman, PhD, Bahija Jallal, PhD, Mohammad Luqman, PhD
Journal: Blood
Blood (2005) 106 (11): 3470.
https://doi.org/10.1182/blood.V106.11.3470.3470
Published: 2005
Journal Articles

CHIR-12.12, an Antagonist Anti-CD40 Antibody, Exhibits Greater ADCC Than Rituximab Against a Variety of Malignant B Cells: Evaluation of FcγRIIIa Polymorphism and ADCC Response.

Mohammad Luqman, PhD, Xia Tong, MSc, Xiaohong Niu, BS, Pablo Garcia, PhD, Michel Faure, PhD, Asha Yabannavar, PhD, Bahija Jallal, PhD
Journal: Blood
Blood (2005) 106 (11): 1472.
https://doi.org/10.1182/blood.V106.11.1472.1472
Published: 2005
Journal Articles

Antagonist Anti-CD40 Antibody CHIR-12.12 Causes Tumor Regression and Prolongs Survival in Multiple Myeloma Xenograft Models.

Li Long, Ph.D., Xia Tong, M.Sc., Montesa Patawaran, B.Sc., Lea Aukerman, Ph.D., Bahija Jallal, Ph.D., Mohammad Luqman, Ph.D.
Journal: Blood
Blood (2004) 104 (11): 4888.
https://doi.org/10.1182/blood.V104.11.4888.4888
Published: 2004
Journal Articles

Antagonist Anti-CD40 Monoclonal Antibody, CHIR-12.12, Inhibits Growth of a Rituximab-Resistant NHL Xenograft Model and Achieves Synergistic Activity When Combined with Ineffective Rituximab.

Li Long, Ph.D., Xia Tong, M.Sc., Montesa Patawaran, B.Sc., Lea Aukerman, Ph.D., Julie Klinger, Ph.D., Bahija Jallal, Ph.D., Mohammad Luqman, Ph.D.
Journal: Blood
Blood (2004) 104 (11): 3281.
https://doi.org/10.1182/blood.V104.11.3281.3281
Published: 2004